[{"orgOrder":0,"company":"Bal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bal Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bal Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bal Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bal Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Balflu (favipiravir) is a RNA-directed RNA polymerase inhibitor, which is approved for the treatment of patients with mild to moderate Covid-19 Infection.

                          Brand Name : Balflu

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 25, 2021

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          BalPharma